We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BEAM stock rises 23% in six months as base-editing pipeline updates boost investor confidence.
BEAM reported positive phase I/II BEACON data for risto-cel in SCD, with BLA expected by 2026.
Beam Therapeutics secured a $500M Sixth Street credit facility, extending its cash runway into mid-2029.
Shares of Beam Therapeutics (BEAM - Free Report) have surged 23% over the past six months, reflecting growing investor confidence in its base-editing gene therapy platform and progress across its clinical pipeline.
The company is advancing several gene-editing therapies across its pipeline and reported encouraging updates from key programs.
Investor confidence strengthened following the company's fourth-quarter 2025 earnings update, which highlighted steady progress across its gene-editing pipeline and reaffirmed upcoming clinical and regulatory milestones.
Over the past year, Beam Therapeutics’ shares have risen 4% compared with the industry’s 16.6% growth.
Image Source: Zacks Investment Research
Positive clinical updates from its lead program, risto-cel in the phase I/II BEACON study for sickle cell disease (SCD), showed a differentiated treatment profile and strengthened expectations for a potential biologics license application (BLA) submission by the end of 2026.
Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for the treatment of glycogen storage disease type 1a (GSD1a) and alpha-1 antitrypsin deficiency (AATD), respectively, underscoring the potential of its precision gene-editing technology.
BEAM-301 is currently in a phase I/II study, with initial data expected in 2026. Meanwhile, for BEAM-302, BEAM has aligned with the FDA on a potential accelerated approval pathway based on 12-month alpha-1 antitrypsin (AAT) biomarker data and plans to enroll additional patients at the selected optimal dose to support a future BLA submission.
Additional pipeline advancements include BEAM-103, being studied for SCD, and BEAM-304, a liver-targeted therapy for phenylketonuria. BEAM plans to file an investigational new drug application with the FDA for BEAM-304 in 2026.
Encouraging clinical data and the possibility of accelerated regulatory pathways have increased optimism about Beam’s future commercial prospects, helping drive the stock higher in recent months.
Strong Financial Position
Beam has historically maintained a large cash runway, which reassures investors that it can fund ongoing clinical development without near-term dilution concerns.
In February, BEAM secured a $500 million non-dilutive senior credit facility from Sixth Street to fund the potential launch of risto-cel in SCD. The deal includes a $100 million upfront payment, up to $300 million tied to clinical, regulatory, and commercial milestones and an optional $100 million tranche over a seven-year term.
Beam ended 2025 with $1.25 billion in cash, cash equivalents and marketable securities, and the additional financing is expected to extend the company’s cash runway into mid-2029, further strengthening its financial flexibility.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.82. CPRX shares have gained 17% over the past year.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.11 to $1.06. CSTL shares have risen 39.3% over the past year.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 34.69%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $8.28 to $9.00 for 2026. Over the past year, shares of ANIP have surged 24.1%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
Key Takeaways
Shares of Beam Therapeutics (BEAM - Free Report) have surged 23% over the past six months, reflecting growing investor confidence in its base-editing gene therapy platform and progress across its clinical pipeline.
Positive Clinical Progress Boosted Investors’ Confidence
The company is advancing several gene-editing therapies across its pipeline and reported encouraging updates from key programs.
Investor confidence strengthened following the company's fourth-quarter 2025 earnings update, which highlighted steady progress across its gene-editing pipeline and reaffirmed upcoming clinical and regulatory milestones.
Over the past year, Beam Therapeutics’ shares have risen 4% compared with the industry’s 16.6% growth.
Image Source: Zacks Investment Research
Positive clinical updates from its lead program, risto-cel in the phase I/II BEACON study for sickle cell disease (SCD), showed a differentiated treatment profile and strengthened expectations for a potential biologics license application (BLA) submission by the end of 2026.
Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for the treatment of glycogen storage disease type 1a (GSD1a) and alpha-1 antitrypsin deficiency (AATD), respectively, underscoring the potential of its precision gene-editing technology.
BEAM-301 is currently in a phase I/II study, with initial data expected in 2026. Meanwhile, for BEAM-302, BEAM has aligned with the FDA on a potential accelerated approval pathway based on 12-month alpha-1 antitrypsin (AAT) biomarker data and plans to enroll additional patients at the selected optimal dose to support a future BLA submission.
Additional pipeline advancements include BEAM-103, being studied for SCD, and BEAM-304, a liver-targeted therapy for phenylketonuria. BEAM plans to file an investigational new drug application with the FDA for BEAM-304 in 2026.
Encouraging clinical data and the possibility of accelerated regulatory pathways have increased optimism about Beam’s future commercial prospects, helping drive the stock higher in recent months.
Strong Financial Position
Beam has historically maintained a large cash runway, which reassures investors that it can fund ongoing clinical development without near-term dilution concerns.
In February, BEAM secured a $500 million non-dilutive senior credit facility from Sixth Street to fund the potential launch of risto-cel in SCD. The deal includes a $100 million upfront payment, up to $300 million tied to clinical, regulatory, and commercial milestones and an optional $100 million tranche over a seven-year term.
Beam ended 2025 with $1.25 billion in cash, cash equivalents and marketable securities, and the additional financing is expected to extend the company’s cash runway into mid-2029, further strengthening its financial flexibility.
Beam Therapeutics Inc. Price and Consensus
Beam Therapeutics Inc. price-consensus-chart | Beam Therapeutics Inc. Quote
BEAM’s Zacks Rank & Stocks to Consider
Beam Therapeutics currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) and Castle Biosciences (CSTL - Free Report) , both currently sporting a Zacks Rank #1 (Strong Buy), and ANI Pharmaceuticals (ANIP - Free Report) , which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.82. CPRX shares have gained 17% over the past year.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.11 to $1.06. CSTL shares have risen 39.3% over the past year.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 34.69%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $8.28 to $9.00 for 2026. Over the past year, shares of ANIP have surged 24.1%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.